Home › Rhabdomyosarcoma › Pennsylvania › Philadelphia
Rhabdomyosarcoma clinical trials in Philadelphia, PA
4 studies for Rhabdomyosarcoma are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecruitingPhase 1
- The Children's Hospital of Philadelphia (CHOP), Philadelphia
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
RecruitingPhase 3
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25 mi away
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RecruitingPhase 1/2
- Children's Hospital of Philadelphia, Philadelphia
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
RecruitingPhase 1/2
- Children's Hospital of Philadelphia, Philadelphia
Rhabdomyosarcoma trials in other cities
- Houston, TX6 studies
- Memphis, TN6 studies
- Washington, DC5 studies
- Salt Lake City, UT4 studies
- Boston, MA4 studies
- Seattle, WA3 studies
- Dallas, TX3 studies
- Birmingham, AL3 studies
- The Bronx, NY3 studies
- Baltimore, MD3 studies
- Aurora, CO3 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.